HeartFlow Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 revenue grew 41% year-over-year to $52.6 million, driven by strong FFRCT and Plaque adoption, with gross margin rising to 80.5%. Full-year guidance was raised for both total and Plaque-specific revenue, and the platform expanded with PCI Navigator and a growing AI data asset.
-
AI-powered platform for coronary artery disease diagnosis is expanding rapidly, leveraging a proprietary, FDA-cleared, and reimbursed technology suite. Key growth drivers include Plaque Analysis, new product launches, and entry into the high-risk asymptomatic market, supported by a robust clinical and data infrastructure.
-
AI-powered coronary artery disease solutions achieved record account growth and strong financial results in 2025, with Plaque Analysis poised to drive further expansion in 2026. The company targets profitability by mid-2028 and is investing in clinical evidence, education, and new product launches to capture a growing TAM.
Fiscal Year 2025
-
Q4 revenue grew 40% year-over-year to $49.1M, with strong FFRct and Plaque Analysis adoption and record installed base expansion. FY2026 guidance projects 24–26% revenue growth, margin expansion, and accelerating plaque contribution, supported by new product launches and favorable reimbursement trends.
-
AI-powered coronary disease diagnostics platform is expanding rapidly, with strong clinical validation, a growing installed base, and a robust sales force. Plaque Analysis is set to broaden the addressable market, with significant payer coverage expected by 2026. Gross margins are improving due to automation and scale.
-
Q3 2025 revenue grew 41% year-over-year to $46.3M, driven by strong AI platform adoption and a rapidly expanding installed base. Gross margin improved, losses narrowed, and the company is well-capitalized post-IPO, with 2025 revenue guidance set for 37.5–38% growth.
-
AI-driven coronary artery disease diagnostics are seeing rapid adoption, with strong Q2 growth and expanding gross margins. New Plaque Analysis technology is poised to drive the next wave of growth, while the company remains focused on U.S. expansion and converting the standard of care.